Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC) Raised to “Hold” at Wall Street Zen

Frazier Life Sciences Acquisition Corp. II (NASDAQ:FLSC) was upgraded by analysts at Wall Street Zen to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

Frazier Life Sciences Acquisition Corp. II Price Performance

FLSC opened at $10.30 on Friday. Frazier Life Sciences Acquisition Corp. II has a 1 year low of $10.18 and a 1 year high of $10.63.

Insider Buying and Selling at Frazier Life Sciences Acquisition Corp. II

In other news, CEO Albert Cha purchased 300,000 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was bought at an average cost of $10.00 per share, with a total value of $3,000,000.00. Following the purchase, the chief executive officer directly owned 300,000 shares of the company’s stock, valued at approximately $3,000,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Frazier Life Sciences Acquisition Corp. II Company Profile

Frazier Life Sciences Acquisition Corp. II is a special purpose acquisition company, or SPAC, focused on identifying and combining with a business in the life sciences sector. The company does not operate a conventional commercial business and was formed to pursue a merger, acquisition, or similar business combination.

Its target opportunities may include companies involved in biotechnology, pharmaceuticals, medical devices, diagnostics, or other healthcare-related technologies. The company’s objective is to provide a publicly traded platform for a private life sciences business through a business combination.

Frazier Life Sciences Acquisition Corp.